ATE442134T1 - Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe - Google Patents

Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe

Info

Publication number: ATE442134T1
Authority: AT; Austria
Prior art keywords: propranolol; pharmaco; release; multiparticular; timed
Prior art date: 2001-10-04

Application number

AT02766476T

Other languages

English (en)

Inventor

Phillip Percel

Gopi Venkatesh

Krishna Vishnupad

Original Assignee

Eurand Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-04

Filing date

2002-10-02

Publication date

2009-09-15

2002-10-02 Application filed by Eurand Inc filed Critical Eurand Inc

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE442134T1 publication Critical patent/ATE442134T1/de

Links

AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 title abstract 4
229960003712 propranolol Drugs 0.000 title abstract 2
238000013265 extended release Methods 0.000 title 1
239000011324 bead Substances 0.000 abstract 2
230000027288 circadian rhythm Effects 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
239000002327 cardiovascular agent Substances 0.000 abstract 1
229940125692 cardiovascular agent Drugs 0.000 abstract 1
230000002060 circadian Effects 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
238000012377 drug delivery Methods 0.000 abstract 1
239000008187 granular material Substances 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
239000008188 pellet Substances 0.000 abstract 1
230000003285 pharmacodynamic effect Effects 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Detergent Compositions (AREA)

AT02766476T 2001-10-04 2002-10-02 Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe ATE442134T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/971,167 US6500454B1 (en)	2001-10-04	2001-10-04	Timed, sustained release systems for propranolol
PCT/US2002/031535 WO2003028708A1 (en)	2001-10-04	2002-10-02	Timed, sustained release multi-particulate dosage forms of propranolol

Publications (1)

Publication Number	Publication Date
ATE442134T1 true ATE442134T1 (de)	2009-09-15

Family

ID=25518009

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02766476T ATE442134T1 (de)	2001-10-04	2002-10-02	Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe

Country Status (12)

Country	Link
US (2)	US6500454B1 (de)
EP (1)	EP1432411B1 (de)
JP (1)	JP4369752B2 (de)
KR (1)	KR101090719B1 (de)
AT (1)	ATE442134T1 (de)
AU (1)	AU2002330211B2 (de)
CA (1)	CA2462637C (de)
DE (1)	DE60233668D1 (de)
ES (1)	ES2333306T3 (de)
MX (1)	MXPA04003234A (de)
NO (1)	NO335070B1 (de)
WO (1)	WO2003028708A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6500454B1 (en) *	2001-10-04	2002-12-31	Eurand Pharmaceuticals Ltd.	Timed, sustained release systems for propranolol
US9358214B2 (en) *	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US8367111B2 (en) *	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
US7967756B2 (en) *	2003-09-18	2011-06-28	Cardiac Pacemakers, Inc.	Respiratory therapy control based on cardiac cycle
US7387793B2 (en) *	2003-11-14	2008-06-17	Eurand, Inc.	Modified release dosage forms of skeletal muscle relaxants
US20050142203A1 (en) *	2003-12-30	2005-06-30	Grant Heinicke	Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
CA2556220A1 (en) *	2004-02-11	2005-08-25	Athpharma Limited	Chronotherapeutic compositions and methods of their use
JP2005306778A (ja) *	2004-04-21	2005-11-04	Basf Ag	徐放性製剤及びその製造方法
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
WO2006039491A1 (en) *	2004-10-01	2006-04-13	Reliant Pharmaceuticals, Inc.	Treating morning migraines with propanolol
US20060240043A1 (en) *	2004-10-08	2006-10-26	Meyerson Laurence R	Methods and compositions for treating migraine pain
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
NZ589750A (en)	2004-10-21	2012-07-27	Aptalis Pharmatech Inc	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060099258A1 (en) *	2004-11-05	2006-05-11	Grant Heinicke	Propranolol formulations
US20060099259A1 (en) *	2004-11-05	2006-05-11	Grant Heinicke	Propranolol formulations
US20060182806A1 (en) *	2004-11-08	2006-08-17	Mintong Guo	Extended-release propranolol composition
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
ATE481096T1 (de)	2005-04-06	2010-10-15	Adamas Pharmaceuticals Inc	Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
AU2013273835B2 (en) *	2005-05-02	2016-07-07	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
EP1915137B8 (de)	2005-08-10	2013-09-11	ADD Advanced Drug Delivery Technologies, Ltd.	Orales präparat mit kontrollierter freisetzung
CN101410094B (zh) *	2006-01-27	2013-04-17	阿普塔利斯制药股份有限公司	包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
KR20140088230A (ko) *	2006-01-27	2014-07-09	앱탈리스 파마테크, 인코포레이티드	약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
CA2642275A1 (en)	2006-02-13	2007-08-23	Vanda Pharmaceuticals, Inc.	Stable dosage formulations of imidazolylalkyl-pyridines
US8846100B2 (en) *	2006-05-12	2014-09-30	Shire Llc	Controlled dose drug delivery system
JP2009538355A (ja) *	2006-05-26	2009-11-05	オースペックス・ファーマシューティカルズ・インコーポレイテッド	ジューテリウム化アミノグリシジル化合物
US20080069878A1 (en) *	2006-08-31	2008-03-20	Gopi Venkatesh	Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
WO2008027557A2 (en) *	2006-08-31	2008-03-06	Spherics, Inc.	Topiramate compositions and methods of enhancing its bioavailability
US8298576B2 (en)	2006-11-17	2012-10-30	Supernus Pharmaceuticals, Inc.	Sustained-release formulations of topiramate
MX2009003911A (es) *	2006-12-04	2009-05-28	Supernus Pharmaceuticals Inc	Formulaciones de liberacion inmediata, mejoradas de topiramato.
US20080187579A1 (en) *	2007-02-01	2008-08-07	Pavan Bhat	Extended-release dosage form
US20080226715A1 (en) *	2007-03-16	2008-09-18	Albert Cha	Therapeutic compositions and methods
EP2222301B1 (de)	2007-12-13	2014-10-08	Vanda Pharmaceuticals Inc.	Verfahren und zusammensetzung zur behandlung einer erkrankung, die durch den alpha-adrenozeptor vermittelt wird
WO2009076664A1 (en)	2007-12-13	2009-06-18	Vanda Pharmaceuticals Inc.	Method and composition for treating a serotonin receptor-mediated condition
WO2010096820A1 (en) *	2009-02-23	2010-08-26	Eurand, Inc.	Controlled release compositions comprising anti-cholinergic drugs
MX337603B (es)	2009-11-30	2016-03-10	Adare Pharmaceuticals Inc	Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
CN102958515A (zh)	2009-12-02	2013-03-06	阿普塔利斯制药有限公司	非索非那定微胶囊及含有非索非那定微胶囊的组合物
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
CN107028900A (zh)	2010-12-02	2017-08-11	艾戴尔医药公司	快速分散颗粒、口腔崩解片以及方法
US20160143864A1 (en) *	2013-07-09	2016-05-26	Sun Pharmaceutical Industries Limited	Extended-release pharmaceutical compositions of metoprolol
CN105287394A (zh) *	2015-11-19	2016-02-03	哈尔滨圣吉药业股份有限公司	一种盐酸普萘洛尔缓释微丸及其制备方法
US20190060287A1 (en)	2017-08-28	2019-02-28	Adare Pharmaceuticals, Inc.	Tizanidine formulations
JP2019052115A (ja) *	2017-09-15	2019-04-04	国立研究開発法人理化学研究所	医薬組成物
GB2628566A (en)	2023-03-29	2024-10-02	Novumgen Ltd	An orally rapidly disintegrating tablet of propranolol and its process of preparation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US48A (en) *		1836-10-11		Turnout fob
GB1561204A (en) *	1977-06-01	1980-02-13	Ici Ltd	Sustained release pharmaceutical composition
US4248857A (en) *	1979-08-09	1981-02-03	American Home Products Corporation	Sustained release pharmaceutical compositions
US4851229A (en)	1983-12-01	1989-07-25	Alza Corporation	Composition comprising a therapeutic agent and a modulating agent
US4894240A (en)	1983-12-22	1990-01-16	Elan Corporation Plc	Controlled absorption diltiazem formulation for once-daily administration
SE457505B (sv) *	1984-01-10	1989-01-09	Lejus Medical Ab	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4728512A (en)	1985-05-06	1988-03-01	American Home Products Corporation	Formulations providing three distinct releases
GB8518301D0 (en)	1985-07-19	1985-08-29	Fujisawa Pharmaceutical Co	Hydrodynamically explosive systems
US5011692A (en)	1985-12-28	1991-04-30	Sumitomo Pharmaceuticals Company, Limited	Sustained pulsewise release pharmaceutical preparation
AU591248B2 (en)	1986-03-27	1989-11-30	Kinaform Technology, Inc.	Sustained-release pharaceutical preparation
US5238686A (en)	1986-03-27	1993-08-24	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
IE58401B1 (en)	1986-06-20	1993-09-08	Elan Corp Plc	Controlled absorption pharmaceutical composition
US5026559A (en)	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US4983401A (en)	1989-05-22	1991-01-08	Kinaform Technology, Inc.	Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
IT1246382B (it) *	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5017381A (en)	1990-05-02	1991-05-21	Alza Corporation	Multi-unit pulsatile delivery system
IE61651B1 (en)	1990-07-04	1994-11-16	Zambon Spa	Programmed release oral solid pharmaceutical dosage form
US5286497A (en)	1991-05-20	1994-02-15	Carderm Capital L.P.	Diltiazem formulation
US5229135A (en)	1991-11-22	1993-07-20	Prographarm Laboratories	Sustained release diltiazem formulation
US5260068A (en)	1992-05-04	1993-11-09	Anda Sr Pharmaceuticals Inc.	Multiparticulate pulsatile drug delivery system
US5260069A (en)	1992-11-27	1993-11-09	Anda Sr Pharmaceuticals Inc.	Pulsatile particles drug delivery system
US5376384A (en)	1992-12-23	1994-12-27	Kinaform Technology, Inc.	Delayed, sustained-release pharmaceutical preparation
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
US5536507A (en)	1994-06-24	1996-07-16	Bristol-Myers Squibb Company	Colonic drug delivery system
US6103263A (en) *	1994-11-17	2000-08-15	Andrx Pharmaceuticals, Inc.	Delayed pulse release hydrogel matrix tablet
EP0714663A3 (de)	1994-11-28	1997-01-15	Lilly Co Eli	Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5567441A (en)	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
US5837284A (en)	1995-12-04	1998-11-17	Mehta; Atul M.	Delivery of multiple doses of medications
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
US5837379A (en) *	1997-01-31	1998-11-17	Andrx Pharmaceuticals, Inc.	Once daily pharmaceutical tablet having a unitary core
US6162463A (en)	1997-05-01	2000-12-19	Dov Pharmaceutical Inc	Extended release formulation of diltiazem hydrochloride
US5840329A (en)	1997-05-15	1998-11-24	Bioadvances Llc	Pulsatile drug delivery system
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
US5968554A (en)	1998-07-07	1999-10-19	Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc.	Sustained release pharmaceutical preparation
US6106862A (en) *	1998-08-13	2000-08-22	Andrx Corporation	Once daily analgesic tablet
US6039979A (en)	1999-01-13	2000-03-21	Laboratoires Prographarm	Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6350471B1 (en) *	2000-05-31	2002-02-26	Pharma Pass Llc	Tablet comprising a delayed release coating
US6500454B1 (en) *	2001-10-04	2002-12-31	Eurand Pharmaceuticals Ltd.	Timed, sustained release systems for propranolol

2001
- 2001-10-04 US US09/971,167 patent/US6500454B1/en not_active Expired - Lifetime
2002
- 2002-10-02 DE DE60233668T patent/DE60233668D1/de not_active Expired - Lifetime
- 2002-10-02 JP JP2003532041A patent/JP4369752B2/ja not_active Expired - Fee Related
- 2002-10-02 AU AU2002330211A patent/AU2002330211B2/en not_active Ceased
- 2002-10-02 KR KR1020047005057A patent/KR101090719B1/ko not_active Expired - Fee Related
- 2002-10-02 AT AT02766476T patent/ATE442134T1/de not_active IP Right Cessation
- 2002-10-02 WO PCT/US2002/031535 patent/WO2003028708A1/en not_active Ceased
- 2002-10-02 MX MXPA04003234A patent/MXPA04003234A/es active IP Right Grant
- 2002-10-02 EP EP02766476A patent/EP1432411B1/de not_active Expired - Lifetime
- 2002-10-02 CA CA2462637A patent/CA2462637C/en not_active Expired - Lifetime
- 2002-10-02 ES ES02766476T patent/ES2333306T3/es not_active Expired - Lifetime
- 2002-12-30 US US10/334,052 patent/US20030157173A1/en not_active Abandoned
2004
- 2004-04-28 NO NO20041740A patent/NO335070B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2462637C (en)	2010-12-07
JP4369752B2 (ja)	2009-11-25
CA2462637A1 (en)	2003-04-10
EP1432411A1 (de)	2004-06-30
ES2333306T3 (es)	2010-02-19
KR20040084890A (ko)	2004-10-06
WO2003028708A1 (en)	2003-04-10
MXPA04003234A (es)	2004-08-12
KR101090719B1 (ko)	2011-12-08
NO20041740L (no)	2004-04-28
DE60233668D1 (de)	2009-10-22
US6500454B1 (en)	2002-12-31
AU2002330211B2 (en)	2007-02-01
EP1432411B1 (de)	2009-09-09
US20030157173A1 (en)	2003-08-21
NO335070B1 (no)	2014-09-01
JP2005508922A (ja)	2005-04-07

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE442134T1 (de)	2009-09-15	Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe
PT1123700E (pt)	2004-07-30	Sistemas de libertacao de farmacos de cronometragem pulsavel
HK1047226A1 (zh)	2003-02-14	流体力学平衡口服药输送系统
BRPI0311701B8 (pt)	2021-05-25	formulação farmacêutica de dosagem multiparticulada revestida com liberação controlada de lamotrigina
DE69826113D1 (de)	2004-10-14	R- und s- enantiomere getrennteteile enthaltende dosierungsformen
CY1118946T1 (el)	2018-01-10	Μορφοποιησεις μεθυλφαινυδατης ελεγχομενης αποδεσμευσης
WO2007090091A3 (en)	2007-11-22	Drug delivery systems comprising weakly basic drugs and organic acids
DE60334775D1 (de)	2010-12-16	Mehrstufiges orales arzneimittelsystem mit kontrollierter freisetzung
WO2004112756A8 (en)	2005-04-07	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
JP2005505557A5 (de)	2006-01-12
PT1660037E (pt)	2011-10-24	Suspensão injectável de aripiprazol
ATE396712T1 (de)	2008-06-15	Pharmazeutische zubereitung zur modifizierten freisetzung
HRP20170746T1 (hr)	2017-08-11	Oblici davanja koji su otporni na lomljenje s odgođenim oslobađanjem
MY127952A (en)	2007-01-31	Orally administered controlled drug delivery system providing temporal and spatial control
NZ521799A (en)	2004-12-24	Sustained release paracetamol composition
WO2006022996A3 (en)	2006-12-21	Dosage form containing multiple drugs
CA2503719A1 (en)	2004-05-21	Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases
Rajput et al.	2024	A current era in pulsatile drug delivery system: Drug journey based on chronobiology
PT1171111E (pt)	2003-09-30	Granulado com teor elevado de l-carnitina ou de uma alcanoil l-carnitina particularmente adequado para a producao de comprimidos por compressao directa
Chhabra et al.	2012	The essentials of chronopharmacotherapeutics
ATE401098T1 (de)	2008-08-15	Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
WO2023208241A1 (zh)	2023-11-02	一种吡非尼酮持续性释放口服固体制剂
DeVane et al.	2001	An explanation of the second-dose effect in pharmacokinetics and its meaning for clinical psychopharmacology
Alsalhy et al.	2025	Sustained release of medications in liquid form: utility, advantages, and disadvantages
Lee	2003	By the way, doctor. After a recent blood pressure check, my doctor bumped up my dose of Lotensin [an ACE inhibitor] from 10 milligrams to 20. I had been taking the 10-mg pill in the morning, but my doctor advised me to take the new, higher dose in the evening. He said most strokes and heart attacks happen in the morning, and that I could get better protection by taking the drug right before. But I read in the Health Letter a couple of months ago that you recommend morning intake, so I am confused